You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Moodys
McKesson
Mallinckrodt
McKinsey

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for L-Citrulline

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug L-Citrulline?

L-Citrulline is an investigational drug.

There have been 19 clinical trials for L-Citrulline. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Syndrome, Anemia, Sickle Cell, and Muscular Dystrophy, Duchenne. The leading clinical trial sponsors are Asklepion Pharmaceuticals, LLC, Masih Daneshvari Hospital, and Angiogenix.

There is one US patent protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for L-Citrulline
TitleSponsorPhase
Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) IllnessAsklepion Pharmaceuticals, LLCPhase 2
Supplementing L-citrulline to Overweight Late Asthma oNset PhenotypesNational Heart, Lung, and Blood Institute (NHLBI)Phase 2
Supplementing L-citrulline to Overweight Late Asthma oNset PhenotypesNational Institutes of Health (NIH)Phase 2

See all L-Citrulline clinical trials

Clinical Trial Summary for L-Citrulline

Top disease conditions for L-Citrulline
Top clinical trial sponsors for L-Citrulline

See all L-Citrulline clinical trials

US Patents for L-Citrulline

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
L-Citrulline   Start Trial Seaweed-derived cosmetic compositions Skinergistics Clinical Skin Solutions Inc. (Vancouver, CA)   Start Trial
L-Citrulline   Start Trial Methods for control of flux in metabolic pathways through enzyme relocation The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) GreenLight Biosciences, Inc. (Medford, MA)   Start Trial
L-Citrulline   Start Trial Methods, systems, and arrays for biomolecular analysis Vibrant Holdings, LLC (San Carlos, CA)   Start Trial
L-Citrulline   Start Trial Hair dyeing process using at least one ortho-diphenol and one organic salt of titanium and of a carboxylic acid L'OREAL (Paris, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for L-Citrulline

Drugname Country Document Number Estimated Expiration Related US Patent
L-Citrulline Canada CA2797786 2030-05-07   Start Trial
L-Citrulline Denmark DK2566953 2030-05-07   Start Trial
L-Citrulline European Patent Office EP2566953 2030-05-07   Start Trial
L-Citrulline Spain ES2718844 2030-05-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Moodys
McKesson
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.